Arrowhead Pharmaceuticals, Inc.

ARWR

Financials

10-QQ3 ended 06/30/2608/04/26 10-QQ2 ended 03/31/2605/07/26 10-QQ1 ended 12/31/2502/05/26 10-KFY 202511/25/25 10-K/AFY 202410/10/25

Disclosures

8-KCurrent report08/04/26 8-KCurrent report06/16/26 8-KCurrent report05/07/26 8-KCurrent report03/20/26 8-KCurrent report02/05/26

Prospectuses and Registrations

S-8Registration of securities for employees05/07/26 424B5Prospectus supplement01/09/26 424B5Prospectus supplement01/09/26 FWPFree writing prospectus01/08/26 FWPFree writing prospectus01/08/26

Proxies

DEF 14ADefinitive proxy01/27/26 DEFA14AAdditional proxy materials01/27/26 DEFA14AAdditional proxy materials02/07/25 DEF 14ADefinitive proxy01/29/25 DEFA14AAdditional proxy materials01/29/25

Ownership

Form 4Insider transaction08/20/26 Form 4Insider transaction08/20/26 144Proposed sale of securities08/18/26 144Proposed sale of securities08/18/26 SC 13G/ABeneficial ownership (amended)08/14/26

Other

ARSAnnual report to shareholders01/27/26 305B2305B201/08/26 ARSAnnual report to shareholders01/29/25 ARSAnnual report to shareholders01/29/24 UPLOADLetter from the SEC05/19/23